Twoxar Inc., of Palo Alto, Calif., said its liver cancer candidate, TXR-311, demonstrated positive results in cell-based assays. In a panel of genetically diverse hepatocellular carcinoma (HCC) cell lines, TXR-311 was shown to be potently cytotoxic with an average half maximal inhibitory concentration (IC50) in the nanomolar range.